PROGESTERONE: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Amneal Pharms Ny	PROGESTERONE	progesterone	CAPSULE;ORAL	207724	ANDA	Amneal Pharmaceuticals LLC	65162-807-10	100 CAPSULE in 1 BOTTLE (65162-807-10)	2017-09-11
Amneal Pharms Ny	PROGESTERONE	progesterone	CAPSULE;ORAL	207724	ANDA	Amneal Pharmaceuticals LLC	65162-807-50	500 CAPSULE in 1 BOTTLE (65162-807-50)	2017-09-11
Amneal Pharms Ny	PROGESTERONE	progesterone	CAPSULE;ORAL	207724	ANDA	Amneal Pharmaceuticals LLC	65162-808-10	100 CAPSULE in 1 BOTTLE (65162-808-10)	2017-09-11
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

Summary: The global supply chain for progesterone, a critical hormone used in pharmaceutical formulations for reproductive health, hormone replacement therapy, and oncology, is characterized by a concentrated manufacturing base and a growing demand. Key suppliers operate primarily in China and India, with a smaller presence in Europe. Patent expirations for branded progesterone products have led to increased generic competition, driving demand for reliable, cost-effective API sourcing. Regulatory scrutiny from agencies like the FDA and EMA impacts manufacturing standards and supply chain integrity.

What is the global manufacturing landscape for progesterone API?

The global manufacturing of progesterone Active Pharmaceutical Ingredient (API) is concentrated in a few key regions, with China and India dominating production volume. These regions benefit from established chemical synthesis infrastructure, cost efficiencies, and significant manufacturing capacity.

Key Manufacturing Regions and Their Characteristics:

China: The largest producer of progesterone API globally. Manufacturers often leverage large-scale production facilities and a well-developed chemical industry. Examples include:
- Zhejiang Xianju Pharmaceutical Co., Ltd.: A major player with significant production capacity and a long history in steroid hormone manufacturing.
- Hubei Biocause Pharmaceutical Co., Ltd.: Another substantial Chinese producer of progesterone.
- Ningbo Menovo Pharmaceutical Co., Ltd.: Engaged in the production of various pharmaceutical intermediates and APIs, including progesterone.
- Shandong Xinhua Pharmaceutical Co., Ltd.: A diversified pharmaceutical company with progesterone API manufacturing capabilities.
India: A significant supplier, known for its strong API manufacturing base and expertise in complex chemical synthesis. Indian manufacturers are often competitive on cost and quality. Examples include:
- Shilpa Medicare Ltd.: A prominent Indian pharmaceutical company with API manufacturing facilities, including for steroid hormones.
- Divi's Laboratories Limited: While not solely focused on progesterone, Divi's is a major API manufacturer with capabilities in steroid synthesis.
- Laurus Labs: A growing API manufacturer with a broad portfolio, potentially including progesterone production.
Europe: A smaller but important source of high-quality progesterone API, often focusing on niche markets or specialized formulations. European manufacturers may adhere to stringent regulatory standards. Examples include:
- Kuppfer GmbH (Germany): Historically a producer of steroid hormones.
- Farmabios S.p.A. (Italy): A producer of steroid hormones and derivatives, including progesterone.

Production Volume Estimates: Precise global production volumes for progesterone API are not publicly disclosed by manufacturers. However, industry estimates suggest that China and India collectively account for over 80% of global supply.

What are the key regulatory considerations for progesterone API suppliers?

Progesterone API suppliers must adhere to rigorous regulatory standards set by national and international health authorities to ensure product quality, safety, and efficacy. These regulations impact facility operations, quality control, documentation, and supply chain traceability.

Major Regulatory Bodies and Their Requirements:

U.S. Food and Drug Administration (FDA):
- Good Manufacturing Practices (GMP): Manufacturers must comply with 21 CFR Part 210 and Part 211 for API production. This includes stringent requirements for facility design, equipment, personnel, process validation, and quality control.
- Drug Master Files (DMFs): API manufacturers typically file DMFs with the FDA, providing confidential detailed information about the manufacturing process, facilities, and controls. This allows drug product manufacturers to reference the DMF in their drug applications without disclosing proprietary information.
- Inspections: FDA conducts pre-approval inspections and routine surveillance inspections of manufacturing facilities to ensure compliance.
European Medicines Agency (EMA) and National Competent Authorities:
- EudraLex Volume 4: This outlines EU GMP guidelines for medicinal products and APIs.
- Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP): Suppliers can obtain a CEP from the European Directorate for the Quality of Medicines & HealthCare (EDQM), which demonstrates that the API complies with European Pharmacopoeia standards.
- Inspections: EMA and national agencies conduct inspections of manufacturing sites.
Other National Regulatory Authorities: Agencies in Japan (PMDA), Canada (Health Canada), Australia (TGA), and others have their own GMP and registration requirements.

Key Regulatory Compliance Aspects:

Impurity Profiling: Strict control and monitoring of process-related impurities and degradation products.
Stability Testing: Comprehensive stability studies to determine shelf life and storage conditions.
Supply Chain Security: Measures to prevent counterfeiting and ensure the integrity of the API from manufacturing to the drug product manufacturer.
Audits: Drug product manufacturers conduct rigorous audits of their API suppliers to verify compliance with GMP and other quality agreements.

What is the patent landscape for progesterone and its implications for API suppliers?

The patent landscape for progesterone is largely characterized by expired patents on original molecular entities and formulations, leading to a mature generic market. However, innovation continues in new delivery systems, combination therapies, and specific therapeutic indications, which can create new patent opportunities and influence API demand.

Historical Context:

The original progesterone molecule itself is long out of patent protection.
Many early formulations and methods of use patents have also expired.

Current Patenting Trends:

New Formulations and Delivery Systems: Patents are often filed for innovative drug delivery methods that improve bioavailability, patient compliance, or reduce side effects. Examples include:
- Micronized progesterone formulations for improved oral absorption.
- Vaginal inserts or gels with controlled release profiles.
- Long-acting injectable formulations.
Combination Therapies: Patents may cover progesterone in combination with other active pharmaceutical ingredients for specific therapeutic uses (e.g., hormone replacement therapy, endometriosis treatment).
Specific Therapeutic Indications: New uses for progesterone, especially in areas like neurological disorders or certain cancer treatments, can be protected by method-of-use patents.
Manufacturing Processes: While the molecule is off-patent, novel or significantly improved synthesis routes that offer cost advantages or higher purity may be patentable.

Implications for API Suppliers:

Increased Generic Demand: The expiration of key patents on branded progesterone products has led to a surge in generic competition. This increases the overall demand for progesterone API from multiple generic manufacturers.
Focus on Cost and Quality: With a competitive generic market, API suppliers are pressured to offer competitive pricing while maintaining high-quality standards to meet regulatory requirements.
New Opportunities: Suppliers of high-purity, specially manufactured progesterone API may find opportunities supporting companies developing novel formulations or combination therapies that are still under patent protection.
Supply Chain Reliability: Generic drug manufacturers rely heavily on consistent and reliable supply of high-quality API. API suppliers with strong regulatory compliance and robust manufacturing processes are favored.
Intellectual Property (IP) Due Diligence: Drug product manufacturers must conduct thorough IP due diligence to ensure their product does not infringe on existing patents, especially for novel formulations or indications.

How does demand for progesterone vary across pharmaceutical applications?

The demand for progesterone API is driven by its broad therapeutic applications, with significant use in gynecology, reproductive medicine, and hormone replacement therapy. The increasing prevalence of these conditions globally supports sustained demand.

Primary Pharmaceutical Applications:

Reproductive Health and Gynecology: This is the largest segment for progesterone.
- Hormone Replacement Therapy (HRT): Used in combination with estrogens to manage menopausal symptoms and protect the uterus from endometrial hyperplasia.
- Menstrual Disorders: Treatment of irregular menstruation, amenorrhea (absence of menstruation), and abnormal uterine bleeding.
- Endometriosis: Management of symptoms and reduction of endometrial implants.
- Preterm Birth Prevention: Progesterone therapy, particularly vaginal progesterone, is used to reduce the risk of spontaneous preterm birth in women with a history of such events or with certain risk factors.
- Infertility Treatment: Used in assisted reproductive technologies (ART) such as in vitro fertilization (IVF) to support the luteal phase and implantation.
Obstetrics: As mentioned above, its role in preventing preterm birth is critical.
Oncology:
- Endometrial Cancer: Progesterone can be used to treat certain types of endometrial cancer.
- Prostate Cancer: Investigational uses in hormone-sensitive prostate cancer.
Dermatology: Occasionally used in specific dermatological preparations.
Central Nervous System (CNS) Disorders: Emerging research into progesterone's neuroprotective effects suggests potential applications in conditions like traumatic brain injury, stroke, and multiple sclerosis, though these are largely in investigational stages and not yet significant drivers of commercial API demand.

Demand Drivers:

Aging Global Population: Increases demand for HRT.
Rising Infertility Rates: Boosts demand for ART and associated progesterone use.
Increased Awareness and Diagnosis: Better diagnosis of gynecological conditions leads to higher treatment rates.
Clinical Guidelines: Recommendations from medical bodies endorsing progesterone for specific indications (e.g., preterm birth prevention) drive prescribing patterns.
Generic Availability: The widespread availability of affordable generic progesterone products makes treatment more accessible.

Projected Demand Trends: The global market for progesterone is expected to continue growing at a steady pace, driven by the factors listed above. The increasing focus on women's health and the development of new therapeutic applications will likely sustain or accelerate this growth.

What are the key considerations for sourcing progesterone API?

Sourcing progesterone API requires a multi-faceted approach, balancing cost, quality, regulatory compliance, and supply chain reliability. Pharmaceutical companies must conduct thorough due diligence on potential suppliers to mitigate risks and ensure a stable supply of high-quality API.

Key Sourcing Considerations:

Quality and Purity:
- API Specifications: Ensure the API meets stringent pharmacopeial standards (e.g., USP, EP, JP) and any specific customer requirements for particle size, polymorphic form, and impurity profiles.
- Analytical Capabilities: The supplier must have robust in-house quality control laboratories with validated analytical methods.
- Impurity Control: Detailed knowledge of potential impurities from the synthesis route and validated methods for their detection and quantification.
Regulatory Compliance:
- GMP Certification: The manufacturing site must be GMP-certified by relevant authorities (FDA, EMA, etc.) and consistently pass regulatory inspections.
- DMF/CEP Status: Availability of a complete and up-to-date Drug Master File (DMF) or Certificate of Suitability (CEP) is crucial for regulatory filings.
- Audit Readiness: Suppliers should be prepared for regular quality audits by their customers.
Supply Chain Reliability and Capacity:
- Production Capacity: Assess the supplier's ability to meet current and projected demand, including surge capacity.
- Lead Times: Understand production lead times and typical delivery schedules.
- Geopolitical Risk: Evaluate the stability of the manufacturing region and potential disruptions (e.g., trade policies, environmental regulations, pandemics).
- Dual Sourcing Strategy: For critical APIs like progesterone, consider establishing relationships with at least two qualified suppliers to mitigate single-source dependency.
Cost and Commercial Terms:
- Pricing: Competitive pricing is essential, especially for generic products. However, it should not compromise quality or regulatory compliance.
- Payment Terms: Negotiate favorable payment terms.
- Contractual Agreements: Establish clear supply agreements that define quality standards, delivery schedules, pricing mechanisms, and change control procedures.
Technical Support and Collaboration:
- Technical Expertise: The supplier should possess strong technical expertise in steroid chemistry and manufacturing.
- Change Control: A robust change control process is critical. Any changes in manufacturing processes, equipment, or raw materials must be communicated and approved by the customer in advance.
- Problem Resolution: The supplier should have a responsive team to address any quality or supply issues.

Supplier Evaluation Process:

Initial Screening: Review supplier websites, regulatory filings, and industry reputation.
Request for Quotation (RFQ): Obtain detailed technical and commercial proposals.
On-site Audits: Conduct thorough GMP and quality system audits of manufacturing facilities.
Sample Testing: Evaluate API samples from the supplier in your own laboratories.
Technical Discussions: Engage in in-depth technical discussions to assess capabilities and address concerns.
Reference Checks: Obtain references from other pharmaceutical companies using the supplier's API.

Key Takeaways

Progesterone API manufacturing is concentrated in China and India, with European producers serving niche markets.
Suppliers must adhere to stringent GMP regulations from the FDA, EMA, and other global health authorities, typically filing DMFs or obtaining CEPs.
The patent landscape for progesterone is dominated by off-patent active ingredients, driving significant generic competition and increasing demand for API.
Demand is primarily driven by applications in reproductive health, gynecology, and hormone replacement therapy, with growing interest in oncology and potential CNS uses.
Sourcing considerations include ensuring API quality and purity, regulatory compliance, supply chain reliability, competitive pricing, and strong technical support from suppliers.

Frequently Asked Questions

What are the primary raw materials used in the synthesis of progesterone API? Progesterone is typically synthesized from steroidal precursors, often derived from diosgenin (from yams) or stigmasterol (from soybeans). The synthesis involves a multi-step chemical process.
How does the micronization process affect progesterone API and its end-use products? Micronization reduces the particle size of progesterone API. This increases its surface area, significantly improving its oral bioavailability and absorption by reducing dissolution time. This is critical for oral dosage forms.
What are the typical quality control tests performed on progesterone API? Standard tests include identification (e.g., IR spectroscopy), assay (e.g., HPLC for potency), related substances (impurities via HPLC), residual solvents (GC), heavy metals, water content (Karl Fischer titration), and physical characteristics such as particle size distribution.
What is the role of a Drug Master File (DMF) in the progesterone API supply chain? A DMF filed with regulatory agencies like the FDA contains confidential, detailed information about the API's manufacturing process, facilities, and quality controls. It allows drug product manufacturers to reference this information in their drug applications without direct access to the proprietary details, streamlining the regulatory review process.
Are there any significant environmental concerns associated with progesterone API manufacturing? Chemical synthesis of complex molecules like progesterone can involve the use of various solvents and reagents. Manufacturers must manage waste streams, emissions, and water usage responsibly to comply with environmental regulations and minimize ecological impact.

Citations

[1] U.S. Food & Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) Regulations. Retrieved from https://www.fda.gov/drugs/pharmaceutical-quality-resources/current-good-manufacturing-practice-cgmp-regulations [2] European Medicines Agency. (n.d.). EudraLex - The Rules Governing Medicinal Products in the European Union. Volume 4: Good manufacturing practice. Retrieved from https://ec.europa.eu/health/human-use/eudralex/volume-4_en [3] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificate of Suitability (CEP). Retrieved from https://www.edqm.eu/en/certificate-suitability-cep

Suppliers and packagers for PROGESTERONE

PROGESTERONE

Progesterone Drug Supply Chain Analysis